Eisai has launched lecanemab-irmb as a weekly subcutaneous injection for early Alzheimer's disease, offering home-based dosing as an alternative to intravenous infusion. This approach addresses treatment accessibility and adherence by reducing clinical visits while maintaining the anti-amyloid mechanism shown to slow cognitive decline in early-stage disease.
Key Points
- Weekly subcutaneous injection replaces IV infusion for lecanemab initiation
- Home-based dosing reduces clinic visits and healthcare resource burden
- Requires ongoing MRI monitoring for amyloid-related imaging abnormalities
Longevity Analysis
The shift from IV to subcutaneous administration removes a significant barrier to anti-amyloid therapy — the logistical burden of repeated clinical infusions. For individuals in the early stages of cognitive decline, consistent adherence to disease-modifying treatment depends on accessibility and convenience as much as efficacy. This formulation addresses a practical constraint that often determines whether someone can sustain treatment long enough for the underlying mechanism (slowing amyloid accumulation and associated neuronal dysfunction) to produce measurable cognitive benefit. The broader implication is that treatment delivery method can meaningfully affect real-world outcomes when the therapeutic window for intervention is narrow.
Original published by LT Wire.